Rigel Pharmaceuticals, Inc.
RIGL · Healthcare
$47.50
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
Knight Therapeutics announced that it received regulatory approval from Colombia's health authority (INVIMA) for TAVALISSE (fostamatinib disodium hexahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The company plans to launch the drug in Colombia in the first half of 2027, following its May 2026 launch in Mexico and an expected Q4 2026 launch in Brazil.
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® en Colombie
Knight Therapeutics Inc. (TSX: GUD) announced regulatory approval from Colombia's INVIMA for TAVALISSE® (fostamatinib disodium heptahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The approval marks a significant milestone in Knight's Latin American expansion strategy following its 2022 licensing agreement with Rigel Pharmaceuticals. The company plans to launch TAVALISSE in Colombia in H1 2027, following launches in Mexico (May 2026) and Brazil (Q4 2026).